mRNA 2.0 Immunotherapy for Cancer

Time: 9:00 am
day: Day Two

Details:

  • Improvements in innate immunogenicity of mRNA therapeutics can expand their
    therapeutic window
  • Cancer ribosomes provide a novel opportunity for the design of onco-selective
    mRNAs
  • Stealth, onco-selective, and oncolytic mRNAs can induce tumor regression in
    syngeneic mouse models resistant to check-point inhibitors

Speakers: